Biomaterial Database

Blastic variant of mantle cell lymphoma occurring in immunosuppressed patients. 2002

L R Munro, and P W Johnston, and J R Goodlad, and D J Culligan

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009363	Neoplasm Proteins	Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.	Proteins, Neoplasm
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D015703	Antigens, CD	Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.	CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D016867	Immunocompromised Host	A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.	Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D020522	Lymphoma, Mantle-Cell	A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated,Lymphoma, Centrocytic Small-Cell,Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated,Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated,Lymphoma, Lymphocytic, Intermediate,Lymphoma, Small-Cell, Centrocytic,Mantle-Cell Lymphoma,Mantle-Zone Lymphoma,Diffuse Lymphocytic Lymphoma, Poorly-Differentiated,Lymphocytic Lymphoma, Diffuse, Poorly Differentiated,Centrocytic Small-Cell Lymphoma,Centrocytic Small-Cell Lymphomas,Diffuse Lymphocytic Lymphoma, Poorly Differentiated,Lymphoma, Centrocytic Small Cell,Lymphoma, Mantle Cell,Lymphoma, Mantle-Zone,Lymphomas, Centrocytic Small-Cell,Lymphomas, Mantle-Cell,Lymphomas, Mantle-Zone,Mantle Cell Lymphoma,Mantle Zone Lymphoma,Mantle-Cell Lymphomas,Mantle-Zone Lymphomas,Small-Cell Lymphoma, Centrocytic,Small-Cell Lymphomas, Centrocytic